Giving access to a patented, innovative, and proven next-generation Drug Coated Balloon technology

New Delhi-based medtech firm Translumina, a global leader in interventional cardiovascular medical devices with manufacturing presence in Germany and India, has announced the acquisition of Blue Medical Devices, a Wellinq group company, based out of Helmond, Netherlands. The company incorporated in 2013 produces an innovative basket of balloon catheters including Drug Coated Balloons (DCB) and other speciality balloons for complex coronary interventions.

Notably, Blue Medical DCB catheters, Protégé NC and Protégé SC, significantly overcome the limitations of current DCB technologies and offers high efficacy and safety. The EU-MDR approved DCB catheters have a unique offering of a non-compliant and a semi compliant version. The technology involves a patented drug application technology that prevents any drug loss during the advancement of the device to the lesion resulting in high concentration of the drug at the targeted site.

Drug Eluting Balloons are now being considered a treatment of choice for in-stent restenosis, smaller vessels, bifurcations and multivessel disease. The current estimates project DCB market to be almost 30% of the global drug eluting stents (DES) market in the next 5 years.

The acquisition shall also enable Translumina to use the patented Drug application technology of Blue Medical in other product lines in peripheral and neurovascular interventions complimenting its leadership in unique and innovative dug coating recipes.